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Introduction: Lung cancer is a leading cause of cancer mortality worldwide. Non-invasively
collected biofluids such as exhaled breath condensate (EBC) present a potential sampling me-
dium to detect and study pathological changes implicated in tumourigenesis. Mitochondrial
DNA changes have been implicated in the carcinogenesis process. Consequently, the detection
of mitochondrial changes in EBC could expand our understanding of lung carcinogenesis as well
as identifying specific markers for future studies.
Methods: EBC and saliva was collected from newly diagnosed subjects with lung cancer and con-
trol subjects in a cross-sectional study. The EBC and saliva was analysed formitochondrial DNA D-
loopchanges using aPCR sequencing approach. The sequences obtainedwere compared to paired
salivary DNA and the revised Cambridge Reference Sequence (rCRS) to identify somatic muta-
tions, and quantitative and qualitative differences in mutations were analysed between groups.
Results: A total of 25 subjects (9 NSCLC patients, 10 smokers/ex-smokers and 6 non-smokers)
were recruited. A significantly elevated D-loop mutation rate in the lung cancer group compared
to the control groups was present (7 vs 3.5 for smokers/ex-smokers, and 7 vs. 4 for non-smokers,
pZ 0.034). The recognised mutation T16217C showed specificity for lung cancer.
Conclusions: Mitochondrial DNAmutations aremorecommon in theEBCof patientswith lung can-
cer. This suggests that these processes are associated with the carcinogenesis of lung cancer and
may be a marker of the disease.
ª 2013 Elsevier Ltd. All rights reserved.n and Infection Research Centre, Faculty of Medicine, University of New South Wales, Australia.
.edu.au (P.S. Thomas).
3 Elsevier Ltd. All rights reserved.
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details were obtained via a questionnaire. Ex-smokers wereLung cancer remains the leading cause of cancer death
globally, accounting for 13% of all deaths.1 The low 5-year
survival rate of 15% can be attributed to late diagnosis in
the vast majority of cases,2 for which there are suboptimal
therapies. Exhaled breath condensate (EBC) is a non-
invasive method of sampling the respiratory epithelial lin-
ing fluid.3 Genetic4e7 and epigenetic8 changes in EBC of
patients with lung cancer have demonstrated mixed re-
sults, but these changes may be informative markers of
disease9 and recently tissue studies have highlighted the
potential role of mitochondrial DNA changes in carcino-
genesis and as biomarkers of lung cancer.
Mitochondrial DNA (mtDNA) is a 16,569 base pair (bp)
circular double-stranded molecule coding for 37 genes
including 13 polypeptides involved in respiration and
oxidative phosphorylation.10 mtDNA is more susceptible to
oxidative damage than nuclear DNA due to its proximity to
the electron transport chain, inefficient repair mechanisms
and lack of protective histones.11e13 Somatic mtDNA mu-
tations have been hypothesised to play a part in cancer
through pathways such as mitochondrial respiratory chain
dysfunction which increases reactive oxygen species (ROS)
production,14 interference with cellular apoptosis15,16 and
translocation causing activation of nuclear oncogenes,
although recent studies have identified anti-tumorigenic
mtDNA mutations as well.17
mtDNA mutations accumulate in the D-loop region, a
1,124bp non-coding region containing the major control
elements for mtDNA expression, replication and transcrip-
tion.18 Studies of lung tissue, BAL and sputum have
demonstrated that D-loop mutations are prevalent in lung
tumours19e27 and correlate weakly with clinical character-
istics such as tumour grade and lymph node metastasis.27
EBC may be a non-invasive method of detecting mito-
chondrial markers of lung cancer. Due to its high copy
number and high mutation rate, mutations in the D-loop
region of mtDNA are ideal to study in low-cellularity sam-
ples like EBC, and may play a role in contributing to the
genetic instability involved in carcinogenesis.28 Specifically,
EBC mtDNA may reflect changes observed in studies of lung
tissue and it was hypothesised that a higher somatic mu-
tation rate in patients with lung cancer would be observed
when compared with healthy control subjects.
Materials and methods
Subject recruitment
This cross-sectional observational study was granted ethics
approval (SESAHS HREC04/179). Subjects were recruited
from the Prince of Wales Hospital (POWH), and gave writ-
ten, informed consent. The study population had a
confirmed histological diagnosis of non small cell lung car-
cinoma (NSCLC) by bronchoscopic biopsy or transthoracic
cytological aspiration and were enrolled prior to treatment.
Control subjects were recruited from the inpatient,
outpatient and community populations. Exclusion criteria:
history of chronic respiratory diseases, FEV1/FVC<70%,
known history of lung cancer and recent or currentrespiratory illness (<2 weeks). Demographic and medical
those who had ceased smoking for >1 year.
EBC and saliva collection
Subjects refrained from smoking, eating or drinking 2 h
prior to EBC collection. After rinsing their mouths with
water, subjects provided a saliva sample (average volume
0.5 mL) which was stored at 80 C.
EBC was collected using a custom-made glass condenser
as previously described29,30
Subjects breathed through a unidirectional valve, at a
normal frequency and tidal volume, for 20 min. EBC was
collected on ice at 4 C, aliquoted and deaerated with
argon degassing at 0.4L/min for 1 min, and immediately
stored at 80 C. Unpublished studies demonstrated that
this method does not allow salivary DNA contamination or
cross-over DNA contamination.
Nucleic acid isolation
EBC (minimum volume 400 mL; average 1000 mL) was
concentrated to 200 mL using a SpeedVac SC110A (Thermo
Scientific, Victoria, Australia). DNA was extracted from the
concentrated EBC using a QIAamp DNA Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s protocol
with modifications to increase DNA yield and concentration;
DNA was eluted in 55 mL of pre-heated buffer AE and the
eluate was passed through the column again in a second
elution step. DNA was extracted from saliva using the same
kit using a 100 mL elution volume. The resulting EBC-DNA
and saliva-DNA either immediately underwent PCR ampli-
fication or was stored at 20 C.
Polymerase chain reaction amplification
A 1450 base-pair (bp) segment of the mitochondrial genome
containing the D-loop region was amplified using the for-
ward primer 50-TACTCAAATGGGCCTGTCCT-30 and reverse
primer 50-AGGGTGAACTCACTGGAACG-30. These primers
were custom-designed, based on the revised Cambridge
Reference Sequence (rCRS, accession number: NC_012920),
using the Primer3 software (Whitehead Institute for
Biomedical Research, Cambridge, MA) and submitting to
BLAST search (Basic Local Alignment Search Tool, www.
ncbi.nlm.nih.gov/BLAST/). Primers were purchased from
Invitrogen (Carlsbad, CA, USA).
PCR was performed in 50 mL reactions with 15 mL of EBC-
DNA, 2.5U of Fast Start High Fidelity Taq (Roche Applied
Science, Mannheim, Germany) in supplied PCR buffer,
0.4 mM of each primer, 1.5 mM Mg2þ, 200 mM of deoxy-
ribonucleoside triphosphate (dNTPs) and 5% DMSO. Thermal
cycling was performed on a GeneAmp PCR System 9700
(Applied Biosystems, Victoria, Australia) with an initial
denaturing step at 95 C for 2 min, followed by 42 cycles of
denaturation at 95 C for 30 s, annealing at 55 C for 30 s
and extension at 72 C for 1 min 15 s, and a final extension
at 72 C for 7 min. Salivary DNA PCR was performed on 30 ng
of sample in a final volume of 25 mL using the same reaction
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25 cycles of PCR were used.
A negative control (elution buffer and enzyme without
DNA template) was included in every PCR series.
PCR purification and DNA sequencing
PCR amplicons were run on a 1.5% agarose gel, and
confirmed by comparison to reference bands on a 500-5000
bp DNA ladder (Bioline, London, UK). PCR products were
purified using a PCR purification kit (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions. In every
sample, the first 855 bp of the D-loop (nt 16024-nt 310) was
sequenced in three overlapping segments using nested
sequencing primers (Fig. 1). Sequencing reactions were
performed using the ABI PRISM BigDye Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems, Victoria,
Australia), according to the manufacturer’s instructions,
except that 5% DMSO was added to the reaction mixture to
aid annealing where secondary structures existed. Cycle
conditions were 30 cycles of 96 C for 10 s, 50 C for 5 s, and
60 C for 4 min, followed by 7 min at 4 C, performed on a
GeneAmp PCR System 9700 (Applied Biosystems, Victoria,
Australia). Samples were then cleaned by EDTA/ethanol
precipitation according to the recommended protocol and
dried by evaporation at 90 C. These products were ana-
lysed using capillary sequencing.Duplicate amplifications
were performed on all patient EBC samples, consisting of an
independent PCR and sequencing reaction to exclude PCR
artefacts and sequencing errors.
Sequence analysis
A consensus sequence was constructed for each sample and
aligned to the rCRS using the commercial software Seq-
Scape (Applied Biosystems, Victoria, Australia). The chro-
matographs were then manually screened for somatic
mutations, which were defined as any base change fromFigure 1 Sequencing strategy. Sequencing primers were placed
length heteroplasmy is present (regions shown in red). Primers are n
revised Cambridge reference sequence; F denotes a forward prime
the data obtained with the forward primer; the bottom represent
sequence becomes unreadable in each direction after the homopol
in this figure legend, the reader is referred to the web version ofboth the rCRS and paired saliva from the same patient. This
definition determined which deviations from the rCRS were
germline polymorphisms (appearing in both saliva and EBC)
and which were somatic mutations (appearing only in EBC).
A heteroplasmic mutation was only defined if it occurred in
the sequences obtained from both independent PCR am-
plifications. The analysis was carried out in a blinded
manner, and sequence analysis was repeated a second time
for all sequences.
The sample sequences were compared to nuclear mito-
chondrial sequences (NumtS) downloaded from the UCSC31
to enable the likelihood of co-amplification of nuclear
DNA to be assessed.
Statistical analysis
Statistical analysis was performed using Graph Pad Prism
v.5 software (Graph Pad, La Jolla, CA). Non-parametric
tests were used for comparison of rate of D-loop mutations
as these were discrete data; KruskaleWallis with Dunn’s
multiple comparison test for data where there were mul-
tiple groups and ManneWhitney U test for data where there
were two groups. Fisher’s exact test was used to analyse
categorical data (prevalence of individual mutations be-
tween groups). Correlations were performed using Spear-
man’s test. A two-tailed p-value p < 0.05 was considered to
be statistically significant.
Results
Subject characteristics
Twenty-five subjects were recruited and their characteris-
tics are displayed in Table 1. The lung cancer group was
slightly older than the smokers/ex-smokers and non-
smokers (p < 0.05). No difference in the gender distribu-
tion or smoking history was found.to allow entire D-loop to be sequenced even when C-stretch
umbered according to the position of the 30 of the primer on the
r and R denotes a reverse primer. The top sequence represents
s the sequence from the reverse primer. As can be seen, the
ymer C-stretch. (For interpretation of the references to colour
this article.)
Table 1 Subject characteristics.
Patients with NSCLC
(n Z 9)
Control subjects
Smokers/ex-smoker
(n Z 10)
Non-smokers
(n Z 6)
Age (yrs) 71  3 58  3 58  4
Gender (male/female) 6/3 5/5 3/3
Lung cancer histology
Squamous cell carcinoma 2 N/A N/A
Adenocarcinoma 3 N/A N/A
Large cell carcinoma 4 N/A N/A
Lung cancer stage
Stage I 1 N/A N/A
Stage 2 0 N/A N/A
Stage 3 1 N/A N/A
Stage 4 7 N/A N/A
Pack-years (smokers and ex-smokers) 51  11 32  7 0
914 S.S. Yang Ai et al.Rate of D-loop changes in patients with NSCLC vs.
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PCR amplification yielded a single product for sequencin-
g.Analysis of the median number of D-loop mutations be-
tween the lung cancer, smokers/ex-smokers and non-
smokers groups demonstrated a significant difference be-
tween groups (pZ 0.034), with a higher median number of
mutations in the lung cancer group compared to the
smokers/ex-smokers (7 vs. 3.5, p < 0.05 Fig. 2).
No differences in the prevalence of heteroplasmic mu-
tations between groups was found (p Z 0.85 Fig. 3A)
however a significantly different rate of homoplasmic mu-
tations between groups was present (p Z 0.035), with the
lung cancer group having the highest median number of
homoplasmic mutations compared to both the smokers/ex-Figure 2 Number of D-loop mutations in EBC-DNA of lung
cancer patients (n Z 9), smokers/ex-smokers (n Z 10) and
non-smokers (n Z 6). There was a significant difference be-
tween groups (pZ 0.034, KruskaleWallis test) with the median
number of mutations in the lung cancer group being higher
than the smokers/ex-smokers group (p < 0.05, Dunn’s multiple
comparisons test). Bars represent medians. *p < 0.05.smokers and non-smokers groups (2 vs. 0 and 2 vs. 1
respectively, p < 0.05 Fig. 3B).
Mutations by clinicopathological features
No significant difference in mutation rates between the
histological lung cancer subtypes or by stage was found.
There was no correlation between mutation incidence and
age when all subjects (lung cancer subjects, smokers/ex-
smokers and non-smokers) were assessed. The frequency of
mutations also did not differ by gender or race. Among
smokers, there was no significant difference in mtDNA
mutation frequency for pack-years, number of cigarettes
smoked per day, year smoked and age at smoking initiation.
Heavy smokers (>40 pack-years) had greater numbers of
mutations than lighter smokers, but the trend was not
statistically significant (p Z 0.16Fig. 4).
Analysis of prevalence of specific mutations
Analysis of the prevalence of specific point mutations
showed that one mutation (T16217C) was associated with
lung cancer (p Z 0.036). The prevalence of the mutations
observed are summarised in Table 2.
A polymorphism was detected in an EBC sample obtained
from a patient with lung cancer. The data was confirmed by
an independent PCR and sequencing analysis, which
demonstrated a heteroplasmic T insertion at nt 60 (www.
hmtdb.uniba.it).
Discussion
mtDNA mutations have been reported in biofluids such as
nipple aspirate,32 BAL, urine19 and others. This is the first
study to demonstrate the feasibility of detecting mtDNA
changes in breath condensate, and as such represents an
original contribution to the field of breath research. This
study highlights the possibility of using this non-invasive
method to detect biomarkers of lung cancer.
In this study population, the D-loop mutation prevalence
in the EBC-DNA of patients with lung cancer was higher than
Figure 3 Number of heteroplasmic (A) and homoplasmic (B) D-loop changes in EBC in those with lung cancer (nZ 9), smoker/ex-
smoker (n Z 10) and non-smoker (n Z 6) control subjects. There was no significant difference in the number of heteroplasmic
mutations between groups (p Z 0.85, KruskaleWallis test), however a significant difference in homoplasmic mutations between
groups was seen (p Z 0.035, KruskaleWallis test), and the lung cancer group had a significantly higher median number of
homoplasmic mutations compared to the smoker/ex-smokers (p < 0.05) and non-smokers (p < 0.05, Dunn’s multiple comparisons
test). Bars represent medians. *p < 0.05.
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mtDNA damage in the cells of the respiratory tract, possibly
caused by increased oxidative damage due to the oxidative
burden induced by neoplasia,33e36 or it may be an reflection
of widespread mitochondrial DNA damage that preceded
and contributed to the carcinogenic process.
It is biologically plausible that thesemutations are caused
by exposure to carcinogens and oxidants such as those in
cigarette smoke. Therefore the EBC mtDNA mutations in
those with lung cancer may be an amalgamation of cigarette
smoke-induced damage preceding neoplastic changes and
oxidative damage exerted by cancer cells. One limitation is
that the control group excluded diseases such as COPDwhich
are common in patients with lung cancer. mtDNA mutationsFigure 4 Number of D-loop mutations in EBC-DNA in heavy
smokers (>40 pack-years, nZ 4) and light smokers (<40 pack-
years, n Z 6). There was a trend towards a higher number of
mutations in the heavy smoking group (p Z 0.16, Man-
neWhitney U test). Bars represent medians.occur at a higher incidence in the lung tissues of smokers,
and there is variability in the mutation rates between
smokers,35 however, all of these studies focused on large-
scale deletions, in particular the 4977-bp ‘common dele-
tion’ and this is the first to study point mutations in smokers
and demonstrate similar inter-individual variability. The
degree of variability may reflect differing susceptibilities of
lung tissue to cigarette smoke-induced damage, as most
smokers do not in fact develop lung cancer.36 Also, some of
the smokers with a higher number of mutations may already
in fact have pre-cancerous changes in their lung tissue, or
have a greater predisposition to developing lung cancer. One
study37 used multiple biopsies taken from patients with lung
cancer to demonstrate that mtDNA mutations present in the
tumour are also found in multiple sites of normal mucosa
distinct from the tumour, suggesting that smoking exposure
may lead to clonal patches of mtDNA dysfunction which
could later undergo neoplastic change.
Interestingly, the majority of the mutations observed in
our study were heteroplasmic in nature [Table 2]. There are
several interpretations of this observation:age-associated
mutations tend to be heteroplasmic38,39 and hence this
may not be a disease-associated phenomenon, and the
degree of heteroplasmic mutation was similar between
groups in this study. In addition EBC theoretically samples
the entire respiratory tract, and as such represents a
mixture of DNA from different parts of the lung. Therefore
although different mutations may become dominant in
certain parts of the lung, the consensus sequence shows
these mutations as heteroplasmic.
Some mutations were found to be homoplasmic, and the
median number of homoplasmic mutations was significantly
higher in the lung cancer group compared to the control
group. Several reasons could exist for this phenomenon:
homoplasmic mutations tend to accumulate in tumours19
perhaps indicating clonal proliferation of cancerous cells,
or reflecting a greater replicative advantage that these
mutations impart.
Table 2 Specific point mutations found in EBC and their prevalence in each group divided into homoplasmic/heteroplasmic
nature, with previously reported associations with disease.
Mutation Lung cancer (n Z 9) Control (n Z 16) Previous reported status
T16093C 0 1 SNP site, breast and prostate tumour
G16129A 3 2 SNP site
T16140C 2 1 SNP site
A16182C 4 4 SNP site, prostate tumour
A16183C 6 6 SNP site, lung and prostate tumour
T16189C 6 7 SNP site, prostate tumour
16189 T del 0 1 SNP site
T16217C 3 0 SNP site, prostate cancer
C16221T 0 1 SNP site
C16223T 2 3 SNP site
C16256T 1 1 SNP site
C16257A 1 4 SNP site
C16261T 1 4 SNP site
T16263C 1 0 SNP site
C16266A 2 1 SNP site
T16352C 1 0 SNP site
T16362C 4 1 SNP site
G16391A 1 0 SNP site, ovarian tumour
A16482G 1 0 SNP site
T16519C 3 5 SNP site, gastric, lung, ovarian and prostate tumour
C41T 0 1 SNP site
T72C 1 3 SNP site
A73G 3 4 SNP site, thyroid and prostate tumours
T146C 0 1 SNP site, ovarian carcinoma, prostate tumour
C150T 4 7 SNP site, lung, thyroid and prostate tumour. Longevity.
T152C 1 0 SNP site, ovarian carcinoma, breast tumour
T199C 1 0 SNP site, ovarian carcinoma
T204C 2 0 SNP site, various tumours
G207A 1 0 SNP site, oral, prostate and thyroid tumours
A210G 2 2 SNP site
T239C 1 1 SNP site, ovarian tumour
T250C 1 0 SNP site
A297C 0 1 SNP site
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known, however one possibility is interference with mtDNA
replication. A recent study40 discovered a major replication
origin at nt 57 of the D-loop, which is only four nucleotides
downstream of the T insertion at nt 60. In addition, an
increased incidence of mtDNA mutations and copy number
are seen in epithelial neoplasia, suggesting that these
contribute to the genetic instability required for neoplastic
progression.28Unfortunately this patient died shortly after
participating in the study from advanced lung cancer, and
no additional samples could be obtained to assess mtDNA
copy number in EBC. Saliva was not obtained from this
patient and therefore it cannot be determined whether this
was a germline polymorphism or somatic mutation, how-
ever its heteroplasmic nature suggests that somatic muta-
tion is more likely. Nevertheless this sample was excluded
from the main analysis of D-loop changes in lung cancer vs.
control subjects, and included in this paper to demonstrate
the utility of this method in detecting potentially patho-
logical mtDNA changes for further study.
Confounding factors of age and smoking history which
are associated with greater mtDNA damage may beimportant.38e41 No correlation between age and mutation
load was found, which may indicate that age is not solely
responsible for the differences in mutation prevalence
observed. A bias may have been introduced by amalgam-
ating all the ex-smoker and smoker subjects into one group,
as lung cancer risk decreases after smoking cessation,42
however, a subgroup analysis reveals that the median
number of mutations was similar between smokers and ex-
smokers in this study (p Z 0.92) and hence it was valid to
combine them into one group.
The interpretation of mitochondrial DNA sequencing can
be affected by the inadvertent co-amplification of nuclear
DNA43 particularly in low-cellularity samples. This was
minimised by designing primers specific to mitochondrial
DNA and comparing the primer sequences and sample se-
quences obtained with known NumtS sequences. In addi-
tion, the comparison of EBC sequences with paired
sequences obtained from the more DNA-rich saliva obtained
with the same primers demonstrated adequate similarity to
rule out nuclear co-amplification. Ideally, nuclear co-
amplification would be excluded by using the primers to
amplify DNA obtained from, for example, RhoO cells43
Mitochondrial DNA mutations in EBC 917however comparison of sample sequences with NumtS
tracks demonstrated that the DNA sequence obtained was
most likely mitochondrial in origin.
Low amounts of DNA in EBC resulted in a limited sample
size. This may impact upon the significance of the results
obtained, however this preliminary study suggests that the
methods are feasible and identifies areas for future
research. Undoubtedly, if the technique were to be used in
a clinical situation, better yields would be required,
although sputum cytology also has a variable yield of cells
from the lower respiratory tract and requires multiple
specimens- this may be the case for EBC also. Initially EBC
samples were obtained from 58 subjects however 15 sam-
ples did not contain enough EBC for analysis (mainly lung
cancer subjects, who were less able to breathe into the
apparatus for sufficient time), and inadequate DNA was
obtained from a further 15 samples (mainly control sub-
jects). Although the exact origin of EBC DNA has yet to be
determined, similar mechanisms may operate as those
proposed in production of circulating cell-free DNA,
including normal cell turnover, lysis of cancer cells, cell
necrosis, apoptosis and spontaneous active release of DNA
by tumours.44 These mechanisms may be less active in
disease-free individuals and may explain why DNA yield was
lower in EBC obtained from control subjects.
As there is overlap in mutation rates between the lung
cancer and control groups, the mutation prevalence may
reflect non-specific oxidative damage and specific muta-
tions may be better biomarkers of lung cancer. This muta-
tion (T16217C) shows specificity for the lung cancer group
and is worthy of future studies, as the D-loop contains the
major control elements for transcription and replication of
mtDNA and accumulation of specific mutations may indi-
cate clonal expansion of neoplastic cells. As much of the D-
loop is non-coding, and most mutations found in this study
were located outside the functional regions of the D-loop,
these mutations are not likely to have caused the lung
cancer but are more likely to be a reflection of widespread
mtDNA damage, which has been shown to promote tumour
cell proliferation or permit tumours to adapt to new envi-
ronments.45 There are reports of some anti-tumorigenic
mtDNA mutations,17 however no mutations were associ-
ated with lower cancer risk in this study population. Prob-
ably such anti-tumorigenic mutations would be found in
functional regions of the mtDNA, such as the respiratory
complex regions,17 which were not studied here. Functional
studies such as the use of transmitochondrial cybrids46 are
required to investigate the pathogenicity of mutations such
as the T16217C mutation. A larger study could be con-
ducted to screen for particular mutations such as those
identified in this study using techniques such as PCR/RFLP
and random mutation capture assay.47
The chance of PCR-induced mutations was minimized by
the use of a high fidelity enzyme as well as performing
duplicate PCR and sequencing reactions. No discrepancies
were found between the two independent analyses for
each sample and therefore the chances that the mutations
identified in this study were PCR artefacts is extremely low.
To confirm reproducibility of our results, 3 EBC samples
were obtained from one subject and the 3 DNA sequences
obtained did not show any discrepancy.As this study aimed
to sample the lower respiratory tract, exclusion of salivarycontamination was vital. Salivary contamination was
excluded by mouth rinsing, a unidirectional valve and saliva
trap, confirmed by amylase assay, and that the salivary DNA
sequence differed than that obtained from EBC.
This preliminary study has verified the feasibility of
detecting D-loop mutations in EBC and demonstrated its
potential as a non-invasive biomarker for lung cancer. In
this study population, the D-loop mutation frequency was
higher in the EBC of patients with lung cancer compared to
control subjects, reflective perhaps of greater mtDNA
damage. Furthermore, the T16217C mutation was associ-
ated with lung cancer, however its functional effect is yet
to be determined. Despite the small study size, this pilot
study has demonstrated the promise of EBC as a method of
investigating pathophysiological mtDNA changes in the
lungs and identifying biomarkers for further study, as well
as a potential screening tool for lung cancer, after identi-
fication of suitable biomarkers.
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